Iloperidone

CHEMBL14376 Phase 4 Onaylandı Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

426.5 g/mol

LogP

4.1

Phase

4

This atypical antipsychotic is used to treat schizophrenia in adults and works by blocking dopamine D2 and serotonin 5-HT2A receptors in the brain. It is associated with a lower incidence of extrapyramidal side effects compared to older antipsychotics. QTc prolongation (a heart rhythm change) is an important consideration, requiring cardiac monitoring in some patients.

Moleküler Ağırlık

426,5000 g/mol

LogP

4,10

TPSA

64,80 Å²

Lipinski RO5

Geçer

Terapötik Alanlar

Schizophrenia Bipolar Disorder Stroke Hypertension Major Depressive Disorder

Etki Mekanizması

Blocks dopamine D2 receptors in the mesolimbic pathway, reducing excessive dopaminergic neurotransmission associated with psychotic symptoms. Many also antagonize serotonin 5-HT2A receptors, which may improve negative symptoms and reduce extrapyramidal side effects.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mekanizma

Blocks dopamine D2 receptors in the mesolimbic pathway, reducing excessive dopaminergic neurotransmission associated with psychotic symptoms. Many also antagonize serotonin 5-HT2A receptors, which may improve negative symptoms and reduce extrapyramidal …

2D Yapı

SVG PNG

Cite this structure

Embed this structure

SMILES

COc1cc(C(C)=O)ccc1OCCCN1CCC(c2noc3cc(F)ccc23)CC1

InChI

InChI=1S/C24H27FN2O4/c1-16(28)18-4-7-21(23(14-18)29-2)30-13-3-10-27-11-8-17(9-12-27)24-20-6-5-19(25)15-22(20)31-26-24/h4-7,14-15,17H,3,8-13H2,1-2H3

Molecular Formula

C24H27FN2O4

HBD / HBA

- / 7

Döndürülebilir Bağlar

8

Ağır Atomlar

31

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Sıkça Sorulan Sorular

This atypical antipsychotic is used to treat schizophrenia in adults and works by blocking dopamine D2 and serotonin 5-HT2A receptors in the brain. It is associated with a lower incidence of extrapyramidal side effects compared to older antipsychotics. QTc prolongation (a heart rhythm change) is an important consideration, requiring cardiac monitoring in some patients.

Blocks dopamine D2 receptors in the mesolimbic pathway, reducing excessive dopaminergic neurotransmission associated with psychotic symptoms. Many also antagonize serotonin 5-HT2A receptors, which may improve negative symptoms and reduce extrapyramidal side effects.

Yes, Iloperidone is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL14376. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 71360. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

PillFYI

Hasta dostu bilgi mi arıyorsunuz?

Iloperidone PillFYI'da

Yapı

Hızlı Veriler

Formül: C24H27FN2O4
Eş Anlamlılar: 1

Dış Bağlantılar

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Tıbbi Sorumluluk Reddi

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.